EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen

Andrew Whiteley, Stephen C Ijioma iD, David Ray, Spencer S Langerman, Ellen Hu, Amy Pierre, Tomer Mark, Habte Yimer

Current Oncology · 02.05.2025 · 32 (5) · 268

DOI: 10.3390/curroncol32050268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 02.05.2025. Verfasst von Andrew Whiteley und 7 weiteren Autor:innen. Beteiligte Einrichtung: Texas Oncology-Baylor Sammons Cancer Center, 3410 Worth Street, Suite 400, Dallas, TX 75246, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Hydrazines, Triazoles, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Karyopharm Therapeutics (United States), Karyopharm Therapeutic Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment for relapsed/refractory multiple myeloma (RRMM) is complex, with several classes of drugs that can be combined into doublet, triplet, or quadruplet regimens. Real-world studies can help to determine the optimal treatment sequences and dosing through observed usage of drugs outside of clinical trials. Previous clinical trials have demonstrated high rates of durable responses in the treatment of patients with triple-class-exposed RRMM with regimens containing selinexor, a first-in-class, orally available selective exportin 1 inhibitor. This study analyzed real-world treatment patterns and survival outcomes using a nationwide electronic health record-derived, deidentified database of patients with RRMM treated with an eligible selinexor-containing, triplet-based regimen, including combinations with dexamethasone and pomalidomide, bortezomib, carfilzomib, or daratumumab. Patients had a real-world overall survival (rwOS) of 14.7 months (95% CI: 10.6, 20.9) and a derived progression-free survival (dPFS) of 4.7 months (95% CI: 3.4, 6.7). Patients with previous exposure to anti-CD38 monoclonal antibodies (mAbs) in the most recent regimen prior to the selinexor treatment had numerically higher survival outcomes (rwOS, 20.9; dPFS, 8.7 months). These data suggest that, in the real-world setting, the use of selinexor triplet regimens is effective in patients with RRMM, especially those with prior exposure to an anti-CD38 mAb in the immediate prior line of therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHydrazinesTriazolesAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleAgedMiddle AgedTreatment OutcomeDexamethasoneAdultAged, 80 and overOligopeptides

Stichwörter der Autor:innen

real-world studyrelapsed/refractory multiple myelomaselinexor

Substanzen

selinexorHydrazinesTriazolesDexamethasonecarfilzomibOligopeptides

Autor:innen und Institutionen

  • Texas Oncology-Baylor Sammons Cancer Center, 3410 Worth Street, Suite 400, Dallas, TX 75246, USA.
  • Karyopharm Therapeutics, Newton, MA 02459, USA.
  • Flatiron Health, Inc., New York, NY 10013, USA.
  • Texas Oncology-Tyler, Tyler, TX 75702, USA.

ORCID-Profile: Stephen C Ijioma

Förderung

  • Karyopharm Therapeutics (United States)
  • Karyopharm Therapeutic Inc.

Zitieren

APA

Whiteley, A., Ijioma, S. C., Ray, D., Langerman, S. S., Hu, E., Pierre, A., Mark, T., & Yimer, H. (2025). Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen. Current Oncology, 32(5), 268. https://doi.org/10.3390/curroncol32050268

Vancouver

Whiteley A, Ijioma SC, Ray D, Langerman SS, Hu E, Pierre A, et al. Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen. Current Oncology. 2025;32(5):268. doi:10.3390/curroncol32050268

BibTeX
@article{Whiteley2025,
  author = {Whiteley, Andrew and Ijioma, Stephen C and Ray, David and Langerman, Spencer S and Hu, Ellen and Pierre, Amy and Mark, Tomer and Yimer, Habte},
  title = {Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen},
  journal = {Current Oncology},
  year = {2025},
  volume = {32},
  number = {5},
  pages = {268},
  doi = {10.3390/curroncol32050268}
}
Kostenlos starten →